173 related articles for article (PubMed ID: 36450607)
1. Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020.
Khakban A; Rodriguez Llorian E; Michaux KD; Patten SB; Traboulsee A; Oh J; Lynd LD;
Neurology; 2023 Feb; 100(9):e899-e910. PubMed ID: 36450607
[TBL] [Abstract][Full Text] [Related]
2. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
3. The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs.
Bebo B; Cintina I; LaRocca N; Ritter L; Talente B; Hartung D; Ngorsuraches S; Wallin M; Yang G
Neurology; 2022 May; 98(18):e1810-e1817. PubMed ID: 35418457
[TBL] [Abstract][Full Text] [Related]
4. History of Asthma in Patients with Chronic Obstructive Pulmonary Disease. A Comparative Study of Economic Burden.
Sadatsafavi M; Tavakoli H; Kendzerska T; Gershon A; To T; Aaron SD; FitzGerald JM;
Ann Am Thorac Soc; 2016 Feb; 13(2):188-96. PubMed ID: 26599154
[TBL] [Abstract][Full Text] [Related]
5. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
[TBL] [Abstract][Full Text] [Related]
6. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study.
Al-Sakran L; Marrie RA; Blackburn D; Knox K; Evans C
BMJ Open; 2019 Nov; 9(11):e033599. PubMed ID: 31772108
[TBL] [Abstract][Full Text] [Related]
7. Ten-Year Trends in Direct Costs of COPD: A Population-Based Study.
Khakban A; Sin DD; FitzGerald JM; Ng R; Zafarí Z; McManus B; Hollander Z; Marra CA; Sadatsafavi M
Chest; 2015 Sep; 148(3):640-646. PubMed ID: 26043120
[TBL] [Abstract][Full Text] [Related]
8. Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study.
Bedouch P; Sadatsafavi M; Marra CA; FitzGerald JM; Lynd LD
PLoS One; 2012; 7(12):e50949. PubMed ID: 23227222
[TBL] [Abstract][Full Text] [Related]
9. Incremental direct medical costs of systemic lupus erythematosus patients in the years preceding diagnosis: A general population-based study.
McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
Lupus; 2018 Jul; 27(8):1247-1258. PubMed ID: 29665755
[TBL] [Abstract][Full Text] [Related]
10. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010-2019.
Zhu W; Tang X; Heyman RA; Cai T; Suh K; Seeger JD; Xia Z
Neurol Ther; 2022 Sep; 11(3):1147-1165. PubMed ID: 35598225
[TBL] [Abstract][Full Text] [Related]
12. Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.
Setayeshgar S; Kingwell E; Zhu F; Zhang X; Zhang T; Marrie RA; Carruthers R; Tremlett H
Mult Scler Relat Disord; 2018 Oct; 25():57-60. PubMed ID: 30036855
[TBL] [Abstract][Full Text] [Related]
13. Predictors of the 10-year direct costs for treating multiple sclerosis.
Moccia M; Palladino R; Lanzillo R; Triassi M; Brescia Morra V
Acta Neurol Scand; 2017 May; 135(5):522-528. PubMed ID: 27357245
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
16. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.
Karampampa K; Gustavsson A; Miltenburger C; Kindundu CM; Selchen DH
J Popul Ther Clin Pharmacol; 2012; 19(1):e11-25. PubMed ID: 22247419
[TBL] [Abstract][Full Text] [Related]
17. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.
Curkendall SM; Wang C; Johnson BH; Cao Z; Preblick R; Torres AM; Knappertz V; Gondek K
Clin Ther; 2011 Jul; 33(7):914-25. PubMed ID: 21684600
[TBL] [Abstract][Full Text] [Related]
18. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
[TBL] [Abstract][Full Text] [Related]
19. The increasing economic burden of multiple sclerosis by disability severity in Australia in 2017: Results from updated and detailed data on types of costs.
Ahmad H; Campbell JA; van der Mei I; Taylor BV; Zhao T; Palmer AJ
Mult Scler Relat Disord; 2020 Sep; 44():102247. PubMed ID: 32554286
[TBL] [Abstract][Full Text] [Related]
20. Ten-year trends in direct costs of asthma: a population-based study.
Tavakoli H; FitzGerald JM; Chen W; Lynd L; Kendzerska T; Aaron S; Gershon A; Marra C; Sadatsafavi M;
Allergy; 2017 Feb; 72(2):291-299. PubMed ID: 27455382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
